{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CELLECTRA%C2%AE+2000", "query": { "intervention": "CELLECTRA® 2000" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CELLECTRA%C2%AE+2000&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T08:26:36.613Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04251117", "title": "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HCC" ], "interventions": [ { "name": "GNOS-PV02", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "CELLECTRA®2000 EP Device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Geneos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-03-01", "completion_date": "2028-11-29", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04251117" }, { "nct_id": "NCT05293249", "title": "dMAbs for Prevention of COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "dMAb AZD5396", "type": "COMBINATION_PRODUCT" }, { "name": "dMAb AZD8076", "type": "COMBINATION_PRODUCT" }, { "name": "CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device", "type": "COMBINATION_PRODUCT" }, { "name": "Hylenex", "type": "DRUG" }, { "name": "CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Pablo Tebas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 61, "start_date": "2022-05-19", "completion_date": "2025-11-21", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293249" }, { "nct_id": "NCT04398433", "title": "INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Papillomatosis" ], "interventions": [ { "name": "INO-3107", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-10-07", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398433" }, { "nct_id": "NCT04642638", "title": "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus Infection", "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "COVID-19 Disease" ], "interventions": [ { "name": "INO-4800", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1307, "start_date": "2020-11-30", "completion_date": "2022-09-13", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 16, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04642638" }, { "nct_id": "NCT04336410", "title": "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronavirus Infection" ], "interventions": [ { "name": "INO-4800", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-04-03", "completion_date": "2022-02-10", "has_results": false, "last_update_posted_date": "2022-04-15", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 3, "location_summary": "Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04336410" }, { "nct_id": "NCT03491683", "title": "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "INO-5401", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2018-05-31", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 21, "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03491683" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" }, { "nct_id": "NCT03502785", "title": "INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "INO-5401", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-07-24", "completion_date": "2025-05-09", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03502785" }, { "nct_id": "NCT03805984", "title": "Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lassa Fever" ], "interventions": [ { "name": "INO-4500", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2019-05-09", "completion_date": "2020-10-21", "has_results": false, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03805984" }, { "nct_id": "NCT04015700", "title": "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics", "type": "BIOLOGICAL" }, { "name": "CELLECTRA®2000 EP Device supplied by Geneos Therapeutics", "type": "DEVICE" }, { "name": "Plasmid encoded IL-12", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-07-14", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-14T08:26:36.613Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015700" } ] }